Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems , ... scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize industries ... wonder material of the 21st Century' by the researchers who were awarded the ...
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... NIOX MINO(R) Set to Dramatically Improve Airway Inflammatory Disease ... Management through Personalized Inflammation Control, NEW PROVIDENCE, N.J., ... that NIOX MINO (http://www.nioxmino.com ), a,hand- held point-of-care ... cleared by the U.S. Food and Drug Administration (FDA).,Physicians ...
... RICHMOND, Va., March 4 Insmed Inc. (Nasdaq,CM: INSM), a developer of ... December 31, 2007., Full-Year 2007 and Recent Company Highlights, ... Completed development of INS-19 (Granulocyte Colony Stimulating ... these products to ...
... First Joint U.S. National Modeling and ... Simulation Meeting on March 11-12, 2008, ... PHST ), a leading provider of software, strategic,consulting, ... its broad-based participation at the inaugural,meeting of the American ...
Cached Biology Technology:FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 2Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 3
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/15/2015)... A new report [ 1 ... of US consumers using mobile banking applications want their mobile ... and voiceprint, instead of having to prove who they are ... Mobile Identity   -   The Fusion of Financial Services, ... the primary channel used by Gen X and Gen Y ...
(Date:6/12/2015)... 2015  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announced the United ... capture, analyze and identify participants of a video ... This system can: , Identify ... subsequent sign-on process is actually the person participating ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... SAN DIEGO , Oct. 9, 2013  Biocom, the association ... community, today announced the endorsement of Nathan Fletcher ... . (Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO ) "A ... of the three major candidates.  Although all three would be ...
... 17, 2013 Reportlinker.com announces that a new ...   Global Next ... http://www.reportlinker.com/p01698925/Global-Next-Generation-Sequencing-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics   TechNavio,s analysts ... grow at a CAGR of 20.78 percent over ...
... two growing seasonsone from May to September and another ... sow crops such as wheat and vegetables; but before ... to clear them for planting. That was probably the ... Imaging Spectroradiometer (MODIS) on NASA,s Aqua satellite captured this ...
Cached Biology News:Biocom Announces 2013 San Diego Mayoral Primary Endorsement 2Global Next Generation Sequencing Market 2012-2016 2Global Next Generation Sequencing Market 2012-2016 3Global Next Generation Sequencing Market 2012-2016 4Global Next Generation Sequencing Market 2012-2016 5Global Next Generation Sequencing Market 2012-2016 6Global Next Generation Sequencing Market 2012-2016 7
... high pressure gradient system uses three ... each providing a flow rate in one microlitre ... detector for added flexibility. System control and ... software and interface unit, CE 4900., Column heater/chillers ...
... isocratic refractive index chromatography system, uses the ... Data processing is provided by the CE ... the high pressure CE 4100 dual piston pump. ... The system can be upgraded to ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
...
Biology Products: